Tag: Calicheamicin
Uncialamycin-based ADC Exhinits Unique Bystander Killing Effect
How can you reach and kill cancer cells that can’t be targeted? The simple answer, use their more susceptible neighboring cells to help -...
Are Small-Format Drug Conjugates a Viable ADC Alternative Solid Tumors?
Antibody-drug conjugates or ADCs are complex immunoconjugates. They are designed to selectively deliver a small-molecules cytotoxic payload to cancer cells. Directed to specific tumor...
New ADC Payload Platform – Synaffix Launches toxSYN™
The Netherlands-based biotech company Synaffix, which has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates or ADCs, launched of a...
FDA Approval for Gemtuzumab Ozogamicin: Reintroduction Based on Favorable Risk:Benefit Profile
The U.S. Food and Drug Administration (FDA) has approved gemtuzumab ozogamicin (Mylotarg™, previously known as CMA-676; Wyeth Pharmaceuticals, a subsidiary of Pfizer) for the...
Drugs and Drug Hunters
All products of the creative process are a reflection of the individual makeup of the inventors. A painting by Mark Rothko looks like a...
